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There have been some concerns regarding the potential for long acting beta-agonist 19 
(LABA) to adversely affect asthma control, despite inhaled corticosteroid and long 20 
acting beta-agonist (ICS/LABA) combination therapy being a commonly used option 21 
at step 3 and above of asthma guidelines.1 In vitro data have shown LABA to exhibit 22 
pro-inflammatory activity due to activation of beta-arrestin and extracellular signal 23 
regulated kinases via non-canonical G protein cyclic adenosine monophosphate (Gs-24 
cAMP)-independent pathways.2 Hence in vivo exposure to formoterol results in an 25 
inflammatory asthma phenotype in mice depleted of endogenous epinephrine.3  26 
Furthermore tachyphylaxis of response occurs rapidly to the canonical effects of 27 
LABA on airway smooth muscle and inflammatory cells due to down-regulation and 28 
uncoupling of  Gs-cAMP. 4 29 
 30 
National and international guidelines advocate a process of assessment, stepwise 31 
adjustment of treatment, and review of response, to achieve the lowest effective 32 
maintenance therapy over the long term. Clinicians are always more inclined to step 33 
up therapy from ICS to ICS/LABA as opposed to performing the converse. For 34 
patients who are controlled on ICS/LABA combination, Global Initiative for Asthma 35 
(GINA) recommends continuing LABA while reducing concomitant ICS dose, while 36 
the US Food and Drug Administration (FDA) suggests that LABA should be stopped 37 
while continuing with the same dose of ICS alone.  38 
 39 
There are some data to suggest that patients well controlled on ICS/LABA may do 40 
less well if they stop their LABA.  A meta-analysis of five trials revealed impaired 41 
asthma control and quality of life when stepping off LABA 5, but did not clearly show 42 
an increase in exacerbations. The FDA mandated safety studies examining adding a 43 
LABA verses maintaining the same dose of ICS, observed that patients who had 44 
entered the trial who were initially maintained on ICS/LABA had an increased 45 
exacerbation risk when they were randomized to ICS alone as compared to   46 
ICS/LABA.6, 7 However, there are no studies that can provide guidance regarding the 47 
conflicting recommendations as to whether patients well controlled on ICS/LABA 48 
should first have their ICS reduced or their LABA discontinued.   49 
 50 
Against this background of uncertainty Rogers et al 8 randomized patients stable on 51 
medium-fixed dose ICS/LABA to receive reduced fixed- dose ICS/LABA, medium 52 
dose ICS alone ,or to continue the same medium dose combination treatment for 48 53 
weeks . Using as a primary outcome a composite of control that included 54 
exacerbations, there were no significant differences in treatment failures between 55 
 3 
any of the three strategies. However, LABA step off was associated with a 70ml 56 
mean decline in FEV1 compared with reducing ICS. There were five hospitalizations 57 
for asthma exacerbations all of which occurred after LABA step off, although 58 
systemic corticosteroid use did not differ between groups. Patients who were taking 59 
reduced dose ICS/LABA fared no worse on any outcomes compared to those taking 60 
a medium dose. A responder analysis for asthma control score (ACT) over 48 weeks 61 
was similar between groups when comparing the cumulative proportion of events 62 
with a score below 19 or with a decrease of at least 3.  63 
 64 
While these data at first sight appear to be reassuring, it is important to understand 65 
that none of the groups did substantially worse than the other. This leads one to the 66 
possible interpretation that the patients in this study were being over-treated prior to 67 
enrollment and thus they were equally able to come off extra ICS or a possibly 68 
superfluous LABA.  Perhaps these patients were already on more ICS than they 69 
needed?  In an observational community study of ICS tapering it was possible to 70 
achieve a 37 % dose reduction without any deterioration in inflammatory markers in 71 
the majority of individuals in conjunction with a commensurate improvement in quality 72 
of life9. Thus, we are still unclear as to whether patients who truly required 73 
combination therapy will be better able to tolerate ICS reduction or LABA elimination.  74 
  75 
With this caveat in mind, it might help to consider the Rogers study as more of a 76 
pragmatic study.  It suggests, that in the context of current prescribing patterns, when 77 
faced with patients who are well controlled on moderate dose ICS/LABA, reducing 78 
ICS may be a reasonable first choice. However, in settings where prescribing may be 79 
more “parsimonious” these results may not hold.  Further, it is important to point out 80 
that carrying this line of reasoning to the next step is not advisable.  Namely, it is not 81 
reasonable to eliminate ICS in patients on low dose ICS/LABA. That strategy results 82 
in increased exacerbations and is therefore not recommended10.   83 
 84 
Are there patients in whom one should favor one type of reduction versus the other?   85 
Adverse effects might guide the clinician. There was more hoarseness in the group 86 
maintained on moderate dose ICS in the Rogers study. Are there biomarkers that 87 
can assist with this decision?  Several come to mind.  Patients who posses one or 88 
two copies of the arginine allele at the 16th amino-acid position of the beta-2 receptor 89 
have been shown to develop worsening of airway hyperresponsiveness when treated 90 
with ICS and formoterol 11 . ICS naïve patients with elevated exhaled nitric oxide 91 
have been shown to develop loss of bronchoprotection with regular use of salmeterol 92 
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12.  It is interesting to speculate whether these, or other, biomarkers could guide us in 93 
making the step-down decision.  94 
   95 
 96 
The issue of overtreatment raised by the Rogers study, brings us to the issue of 97 
variable use of controller therapy.  Single inhaler maintenance and reliever therapy 98 
(SMART) using combinations containing formoterol and ICS, has repeatedly been 99 
shown to be accompanied by improved overall control and lower overall ICS 100 
exposure compared to fixed dose ICS/LABA 13.  Similarly, ICS therapy guided by 101 
symptoms in mild asthma and by albuterol use in moderate asthma has been shown 102 
to be as effective as maintenance controller therapy14, 15.  While the question of 103 
whether to adjust ICS or LABA may still be an issue with our current treatment 104 
paradigm, approaches that educate patients to “auto-adjust” controller therapy may 105 
obviate our need to consider whether to taper ICS or LABA.  Perhaps in many cases 106 
it is best for the patient to do it for us.   107 
  108 
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